Navigation Links
Bayer HealthCare's MEDRAD and Nuance Communications Unveil Industry's First(1) Solution to Automate CT Contrast-Injection Documentation at the annual Radiology Society of North America (RSNA) Meeting

WARRENDALE, Pa., Nov. 27, 2011 /PRNewswire/ -- Today, MEDRAD, INC., a business of Bayer HealthCare, and Nuance Communications, Inc. announce they have collaborated to bring radiology professionals the industry's first interoperability solution to automate documentation of CT contrast-injection data through connectivity between the MEDRAD Certegra® informatics platform and Nuance PowerScribe®| 360 Reporting.  The technology partnership launch is marked by the installation debut at the Mt. Sinai Medical Center (MSMC) in New York.

Through the partnership, Nuance customers can now auto-populate contrast-injection records into radiology reporting systems – eliminating contrast-injection record look-ups and dictation, and driving accuracy and consistency of documentation across physicians. Nuance is first to collaborate in implementing MEDRAD's vendor-neutral informatics interoperability – the implementation of which is being successfully carried out at MSMC. 

"MEDRAD and Nuance have taken a significant step forward in enabling transparent and automated transfer of IV contrast-administration information in radiology," said David S. Mendelson, M.D. FACR, Chief of Clinical Informatics, MSMC.  "Accurate contrast-injection records are automatically incorporated into the final radiology report – delivering true interoperability that ensures high quality care for our patients."  Dr. Mendelson will detail MSMC's technology implementation experience at the Nuance RSNA booth #2816 on Tuesday, November 29 at 11:30 a.m. in Chicago.

"Empowering our customers to have access to core diagnostic information as part of the radiology report is critical and aligns with our commitment to transform and enhance healthcare clinical documentation through advanced technologies and partnerships," said Carina Edwards, Vice President, Healthcare Marketing, Nuance.  "Nuance is committed to the delivery of systems that
capture the full patient story and clinical scenario.  Our work with MEDRAD supports and helps to advance that commitment, making the radiology report more robust than ever before."

"Our Nuance partnership extends the value our Contrast Dose Management™ solution offers – enabling market-leading interoperability that eliminates the need for radiologists to look-up and dictate contrast injection records," said Anthony Cinalli, Vice President, Radiology Marketing and Sales, MEDRAD, INC.  "Radiology professionals throughout the facility can rely on accurate, consistent documentation to reveal actionable insights."

MEDRAD's full line of software and applications that comprise the Certegra® informatics platform will be demonstrated at RSNA booth #5009 in the South Hall.  Attendees can learn how these products address their unique clinical and administrative needs by tailoring an interactive informatics simulation.  To reserve a preferred time slot in advance of RSNA and learn more, visit

Nuance Healthcare's full suite of radiology solutions: PowerScribe | 360 Reporting, PowerScribe 360 Critical Results, PowerScribe 360 Analytics, PowerScribe 360 Decision Support and SpeechMagic will be available for demonstration at booth #2816 at RSNA 2011 in Chicago, November 27 – December 1.  For further information on Nuance's radiology portfolio, please call 1-800-350-4836 or visit:

Nuance Healthcare
Nuance Healthcare, a division of Nuance Communications, is the market leader in providing clinical understanding solutions that accurately capture and transform the patient story into meaningful, actionable information.  Thousands of hospitals, providers and payers worldwide trust Nuance speech-enabled clinical documentation and analytics solutions to facilitate smarter, more efficient decisions across the healthcare enterprise.  These solutions are proven to increase clinician satisfaction and HIT adoption, supporting organizations to achieve Meaningful Use of EHR systems and transform to the accountable care model.  Recognized as "Best-in-KLAS" 2004-2010 for Speech Recognition we invite you to learn more,

MEDRAD develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. MEDRAD is a two-time recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence (2003 and 2010). The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer HealthCare. More company information is available at

Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.9 billion (2010), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries. Find more information at

Alicia Cafardi, MEDRAD, INC., (724) 940-8621,
Holly Spring, Nuance Communications, Inc., (781) 565-5000,

Our online press service is just a click away:

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

(1) Data on File (119378)

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology:
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and ... Pan African Centres of Excellence, and public R&D institutions, civil societies and other ... of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would ... OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE ... Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
Breaking Medicine News(10 mins):